FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma By Ogkologos - February 21, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHO study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Mylan Recalls Injectable Cancer Drug After Particulates Discovered March 20, 2019 Beating cancer by improving the public’s health: the road ahead in... December 4, 2020 ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... June 24, 2021 Genetic discovery could guide treatment for aggressive childhood cancer June 28, 2021 Load more HOT NEWS Foodie Fridays: Watermelon Salad COVID-19: “It could take months to build research up again” Hopes for the future of cancer research – a video from... 20 years on: how we’ve decreased cancer death rates
